Scholar Rock Holding Corporation develops biologic therapies for spinal muscular atrophy and other rare, severe, and debilitating neuromuscular diseases through its myostatin biology platform. Its principal program, apitegromab, is an anti-myostatin therapy being developed for children and adults with SMA, and its pipeline also includes subcutaneous apitegromab and SRK-439.
Recurring company updates include FDA regulatory activity for apitegromab, manufacturing and fill-finish matters tied to the program, quarterly financial results, cash and financing activity such as debt and at-the-market equity programs, and Nasdaq inducement equity grants for new employees. Scholar Rock also reports investor-conference participation and pipeline commentary related to anti-myostatin biology.
Scholar Rock (NASDAQ:SRRK) reported Q4 2025 net loss of $91.0M and FY 2025 net loss of $377.9M, with no revenue. The company had $367.6M in cash and marketable securities as of December 31, 2025, and secured a debt facility of up to $550M to support apitegromab commercialization.
Apitegromab BLA resubmission is planned after a successful FDA reinspection; FDA and EMA milestones and commercial launch activities are expected through 2026.
Summary not available.
Scholar Rock (NASDAQ: SRRK) will present at three investor conferences in March 2026 via fireside chats and webcasts. Management will speak at TD Cowen on March 4, 2026 (1:50 p.m. ET, Boston), Leerink on March 10, 2026 (2:30 p.m. ET, Miami) and Barclays on March 12, 2026 (8:30 a.m. ET, Miami).
A live webcast will be available on the company Investors > Events and Presentations page, and replays will remain accessible for approximately 90 days.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards covering 114,668 shares to seven new hires: 64,226 inducement options and 50,442 inducement restricted stock units. The options carry an exercise price of $47.85, equal to the closing price on February 9, 2026.
Vesting: options vest 25% after one year then quarterly over three years; RSUs vest in four equal annual installments. Awards are issued under the company’s 2022 Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4) and are subject to standard service-based vesting conditions.
Scholar Rock (NASDAQ: SRRK) will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before markets open. Management will host a conference call and live webcast at 8:00 a.m. ET.
Access the live audio webcast via the Investors "Events and Presentations" page on the Scholar Rock website. Telephone participants must register in advance and will receive a confirmation email with dial‑in instructions. An archived replay will be available on the company website for approximately 90 days.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards to two newly hired employees covering an aggregate of 35,200 shares of common stock: inducement stock options for 20,400 shares and inducement restricted stock units for 14,800 shares.
The options have an exercise price of $43.56, equal to the closing price on January 12, 2026. Options vest 25% on the first anniversary of each employee’s start date, with the remaining 75% vesting in 12 equal quarterly installments. RSUs vest in four equal annual installments. All vesting is conditioned on continued service and the awards are issued under the Company’s 2022 Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Scholar Rock (NASDAQ: SRRK) outlined 2026 priorities focused on regulatory approvals and commercialization of apitegromab for children and adults with spinal muscular atrophy (SMA). The company expects a BLA resubmission and U.S. launch in 2026 following FDA interactions and remediation work at a Catalent fill-finish site, and an EMA decision expected mid-2026. Apitegromab development includes a Phase 2 OPAL trial in 2-year-old patients and a planned Phase 2 FORGE trial in FSHD (IND cleared) starting mid-2026. SRK-439 and subcutaneous apitegromab programs are advancing; SRK-439 topline data expected H2 2026. Cash of approximately as of Dec 31, 2025, expected to fund operations into 2027.
Scholar Rock (NASDAQ: SRRK) said management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 7:30 a.m. PST (10:30 a.m. EST).
A live webcast will be available on the company’s Investors > Events and Presentations page at http://investors.scholarrock.com, and a replay will be accessible for approximately 90 days.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards totaling 7,800 shares to two newly hired employees on December 13, 2025. The package comprises inducement stock options for 4,457 shares and inducement restricted stock units for 3,343 shares, issued under the Company’s 2022 Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The inducement options have an exercise price of $45.25 (equal to the closing price on December 8, 2025). Option vesting: 25% on first anniversary of each start date, then the remaining 75% in 12 equal quarterly installments. RSU vesting: four equal annual installments. All vesting is subject to continued employment.
Sun Life partnered with the Kansas City Royals Foundation for the eighth annual Strikeout Diabetes campaign, donating $50,000 to the Boys & Girls Clubs of Greater Kansas City during a game vs the Seattle Mariners.
The initiative has raised more than $280,000 for Kansas City nonprofits since inception and supports health and fitness programs to help prevent type 2 diabetes. Sun Life also runs related programs with the Boston Celtics and the YMCA and has donated over $37 million globally to diabetes causes.